Market Highlights:
Over the past few years, there has been a significant rise in a number of people additives towards opioid agonist drugs overdoses in the United States every day with figure stood up to 115 death toll. It has also witnessed that 21 to 29 percent of patients who are prescribed opioids for chronic pain misuse them, with 8 to 12 percent developing an opioid use disorder. The major companies are organized awareness programs in Asia-Pacific and Middle East region to prescribe painkillers to help patients overcome opiophobia. The opioids drugs is a type of narcotic pain medication that applicable for treatment of severe pain. It is used as an anesthesia, cough suppressant, diarrhea suppressant and to reduce surgical pain. As the numbers of critically ill patients are increasing, demand for orthopedic diseases is also on the rise, leading to a growing demand for opioids drugs. The market study is being classified by Type (Morphine, Codeine, Fentanyl and Meperidine), by Application (Pain Management, Cough Supression and Diarrhea Suppresion) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Key Players:
The prominent players in the Opioids Agonist Drugs are Purdue Pharma L.P (United States), Allergan PLC (Ireland), Sanofi S.A (France), Pfizer, Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Endo Pharmaceuticals, Inc (United States), Actavis Plc (United States), Egalet Corporation (United States), Sun Pharmaceuticals (India), Boehringer Ingelheim GmbH (Germany). and Titan Pharmaceuticals, Inc. (TTNP) (United States).

Major Market Development Highlights
In April 2019, U.S. Food and Drug Administration launched a public education campaign which is beneficial in providing safe removal of unused opioid pain medicines from homes. It also introduced a “Remove and Risk” Campaign that telecast in television, radio and print public announcements that can be used by different organizations, individuals and healthcare providers.
In January 2019, Medicare has introduced new opioid prescribing guidelines which will affect Medicare Part D beneficiaries. Part D plans are projected to limit early opioid dispensing to a 7-day supply or less. This guideline will impact Medicare patients who have not filled an opioid prescription lately. The suppliers then have to predefine the supply timeline or the consumers have to predetermine the lead. Thus, the new guidelines are expected to limit the abuse rate in the United States.

Key Questions Answered in the Report
What will the Opioids Agonist Drugs Market size and the growth rate be in Future?
What are the key factors driving the Opioids Agonist Drugs Market?
What are the key market trends and macro-economic impacting the growth of the Opioids Agonist Drugs Market?
What are the challenges to market growth?
Who are the key vendors in the Opioids Agonist Drugs Market?
What are the market opportunities and threats faced by the vendors in the Opioids Agonist Drugs Market?
Trending factors influencing the market shares of the Players.
What are the key outcomes of the five forces analysis of the Opioids Agonist Drugs Market?

Refer complete Table of Content of Opioids Agonist Drugs Market Study

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Opioids Agonist Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Opioids Agonist Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Opioids Agonist Drugs Manufacturers, Opioids Agonist Drugs Distributors and Suppliers, Opioids Agonist Drugs International Traders, Pharmaceutical Industry Associations, Research and Development Institutes, Government Agencies and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.